Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
出版年份 2018 全文链接
标题
Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-01-30
DOI
10.1002/cpt.1037
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
- (2017) Hong Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Drug Development of Therapeutic Monoclonal Antibodies
- (2016) Diane R. Mould et al. BIODRUGS
- Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
- (2016) Baiteng Zhao et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
- (2016) Anna Alperovich et al. CANCER JOURNAL
- Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia
- (2016) Jenny Dahl et al. Expert Review of Hematology
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
- (2015) Youn H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
- (2015) Madeleine Duvic et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
- (2014) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
- (2014) Valérie F. Cosson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
- (2014) Michinori Ogura et al. CANCER SCIENCE
- CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
- (2013) Tae H. Han et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
- (2011) Manish Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started